Barclays downgrades Scholar Rock stock rating on valuation

Barclays downgraded Scholar Rock (NASDAQ:SRRK) to Equalweight from Overweight and raised its price target to $58 from $55 following the FDA approval of apitegromab (Isembyld). The firm noted that the risk-reward profile is now more balanced, with future upside dependent on strong commercial execution and pipeline expansion beyond spinal muscular atrophy. Despite the approval, the company remains unprofitable, underscoring the importance of successful commercialization.